Tele: 561.316.3330
Breaking Medical Device News

Monday, September 20, 2021


HomeNON PROFITHenry M Jackson Foundation For The Advancement Of Military Medicine Licenses Herpes Virus Vaccine Technology for Advanced Development

Henry M Jackson Foundation For The Advancement Of Military Medicine Licenses Herpes Virus Vaccine Technology for Advanced Development

October 20, 2020

Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) and Citranvi Biosciences (Citranvi), a company led by former vaccine developers and scientists from top pharmaceutical companies, have signed an exclusive licensing agreement to develop vaccine technologies to prevent Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) infections.

Research for these technologies was conducted by DoD researchers at the Uniformed Services University of the Health Sciences (USU) and patented by the Henry M. Jackson Foundation under the USU-HJF Joint Office of Technology Transfer.

“The dangers posed by congenital CMV and EBV are significant,” said Dr. Krishna Prasad, Founder of Citranvi Biosciences, based in North Carolina. “Citranvi is excited to partner with HJF toward the goal of developing vaccines.”

CMV has a significant maternal-to-infant infection rate and is the most common infectious cause of brain damage and sensorineural hearing loss in infants. Nearly 30%–40% of adolescents who contract EBV will develop infectious mononucleosis, which can lead to serious complications such as liver failure, splenic rupture, and hematologic disorders. EBV is also linked with an increased risk for autoimmunity and nearly 140,000 cancer deaths annually. Infections due to CMV and EBV pose significant risks for transplant patients.

The technology can be used to produce recombinant proteins in a multimeric form, thereby increasing the ability of the vaccines to generate protective antibodies.

“Herpesviruses can impact anyone, even warfighters. Consequently, they pose a risk to force readiness,” said HJF President and CEO, Dr. Joseph Caravalho. “HJF’s mission is to advance military medicine and part of that mandate is ensuring our nation’s warfighters are healthy and able to fulfill their mission. The hope is that this partnership with Citranvi will lead to a new vaccine to fight EBV and CMV, ultimately improving force readiness and benefiting warfighters and civilians alike.”

Research for these technologies was conducted at The Uniformed Services University of the Health Sciences (USU). This research was sponsored by USU; however, the information or content and conclusions do not necessarily represent the official position or policy of, nor should any official endorsement be inferred on the part of, USU, the Department of Defense, or the U.S. Government.

The project described was supported by Grant Number 1R21AI073627 from the National Institute of Allergy and Infectious Disease. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Disease or the National Institutes of Health.


Medical Device News Magazine
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

Jonathan Chapman: New President/CEO of Trividia Health

Chapman said, “I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes.”

SOLOPASS® System (Bedside Neuro-Navigation Device) Receives FDA 510(k) Clearance

inTRAvent’s SOLOPASS® system brings simple, portable, bedside neuro-navigation into the intensive care unit.

By using this website you agree to accept Medical Device News Magazine Privacy Policy